Perrigo Company plc (NYSE:PRGO) Shares Bought by Victory Capital Management Inc.

Victory Capital Management Inc. lifted its position in Perrigo Company plc (NYSE:PRGO - Free Report) by 3.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,457,465 shares of the company's stock after acquiring an additional 44,127 shares during the quarter. Victory Capital Management Inc. owned 1.07% of Perrigo worth $40,867,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Headlands Technologies LLC lifted its holdings in Perrigo by 1,942.0% during the 4th quarter. Headlands Technologies LLC now owns 1,409 shares of the company's stock valued at $36,000 after buying an additional 1,340 shares in the last quarter. Parallel Advisors LLC lifted its holdings in Perrigo by 176.9% during the 1st quarter. Parallel Advisors LLC now owns 1,714 shares of the company's stock valued at $48,000 after buying an additional 1,095 shares in the last quarter. First Horizon Advisors Inc. lifted its holdings in Perrigo by 138.3% during the 1st quarter. First Horizon Advisors Inc. now owns 1,754 shares of the company's stock valued at $49,000 after buying an additional 1,018 shares in the last quarter. Fifth Third Bancorp lifted its holdings in Perrigo by 62.0% during the 1st quarter. Fifth Third Bancorp now owns 2,218 shares of the company's stock valued at $62,000 after buying an additional 849 shares in the last quarter. Finally, Blue Trust Inc. lifted its holdings in Perrigo by 110.4% during the 1st quarter. Blue Trust Inc. now owns 2,619 shares of the company's stock valued at $73,000 after buying an additional 1,374 shares in the last quarter. Institutional investors own 95.91% of the company's stock.

Perrigo Stock Up 2.0%

NYSE PRGO traded up $0.56 during trading on Wednesday, reaching $28.11. 821,942 shares of the company's stock traded hands, compared to its average volume of 1,419,900. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.36 and a quick ratio of 1.28. The firm has a market cap of $3.87 billion, a price-to-earnings ratio of -21.46 and a beta of 0.45. The company's 50 day simple moving average is $26.85 and its two-hundred day simple moving average is $26.15. Perrigo Company plc has a 12-month low of $23.14 and a 12-month high of $30.93.

Perrigo (NYSE:PRGO - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.60 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.56 by $0.04. Perrigo had a negative net margin of 4.16% and a positive return on equity of 8.93%. The firm had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter in the previous year, the firm earned $0.29 EPS. The company's quarterly revenue was down 3.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Perrigo Company plc will post 2.56 EPS for the current fiscal year.

Perrigo Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 17th. Shareholders of record on Friday, May 30th were given a dividend of $0.29 per share. This represents a $1.16 annualized dividend and a yield of 4.13%. The ex-dividend date was Friday, May 30th. Perrigo's dividend payout ratio is presently -88.55%.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of Perrigo from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $33.00.

About Perrigo

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.